Agenus Inc. - Common Stock (NQ:AGEN)

7.570 +0.080 (+1.07%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

November 05, 2025

From Agenus Inc.

Via Business Wire

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

October 17, 2025

From Agenus Inc.

Via Business Wire

Examining the Future: Agenus's Earnings Outlook ↗

August 08, 2025

Via Benzinga

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

October 16, 2025

From Agenus Inc.

Via Business Wire

France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

September 09, 2025

From Agenus Inc.

Via Business Wire

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 05, 2025

From Agenus, Inc.

Via Business Wire

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

August 26, 2025

From Agenus Inc.

Via Business Wire

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

August 19, 2025

From Agenus Inc.

Via Business Wire

Monday's pre-market session: top gainers and losers ↗

August 11, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Agenus Posts 48% Q2 Revenue Miss ↗

August 11, 2025

Via The Motley Fool

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

August 11, 2025

From Agenus Inc.

Via Business Wire

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

July 31, 2025

From Agenus Inc.

Via Business Wire

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

July 25, 2025

From Agenus Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 07, 2025

Via Benzinga

Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

July 07, 2025

From Agenus Inc.

Via Business Wire

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

June 17, 2025

From Agenus Inc.

Via Business Wire

Agenus Announces Virtual Annual Shareholders Meeting

June 10, 2025

From Agenus Inc.

Via Business Wire

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang ↗

June 04, 2025

Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing.

Via Benzinga

Agenus Stock Is Trading Higher Tuesday: What's Going On? ↗

June 03, 2025

Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab.

Via Benzinga

Tuesday's pre-market session: top gainers and losers ↗

June 03, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 03, 2025

Via Benzinga

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US

June 03, 2025

From Agenus Inc.

Via Business Wire

Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗

June 03, 2025

Via Benzinga

Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer

May 30, 2025

From Agenus Inc.

Via Business Wire

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 15, 2025

From Agenus Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 12, 2025

Via Benzinga

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025

From Agenus Inc.

Via Business Wire

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

May 12, 2025

From Agenus Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.